A-1210477: Selective MCL-1 Inhibitor for Mechanistic Cancer Research

Executive Summary: A-1210477 is a small-molecule, nanomolar-potency inhibitor of MCL-1, a central anti-apoptotic Bcl-2 family protein upregulated in many cancers. It selectively disrupts the MCL-1/BIM interaction, triggering mitochondrial apoptosis in MCL-1-dependent cell lines (Campbell et al., 2021). The compound shows strong synergy with navitoclax (ABT-263) in vitro. A-1210477 is strictly for research use, as it lacks in vivo stability and is insoluble in standard solvents. APExBIO supplies A-1210477 (SKU B6011) as a gold-standard tool for probing Bcl-2 family dependencies in cancer research [product].

Biological Rationale

MCL-1 (Myeloid cell leukemia-1) is an anti-apoptotic member of the Bcl-2 protein family that maintains mitochondrial membrane integrity by sequestering pro-apoptotic proteins such as BIM, BAX, and BAK (Campbell et al., 2021). Elevated MCL-1 expression is frequently detected in hematologic malignancies and solid tumors, including breast cancer, where it correlates with poor prognosis. The canonical function of MCL-1 in suppressing apoptosis is central to its oncogenic role. BH3-mimetic drugs that target MCL-1, such as A-1210477, provide a rational approach for overcoming apoptosis resistance in MCL-1-dependent cancer cells. Loss or inhibition of MCL-1 leads to mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and caspase activation, culminating in cell death. This mechanistic axis is validated by genetic and pharmacological studies (see also: Table 1).

Mechanism of Action of A-1210477 (MCL-1 inhibitor)

A-1210477 is a BH3 mimetic that binds the hydrophobic groove of MCL-1 with high affinity (Kd = 0.45 nM), competitively inhibiting its interaction with pro-apoptotic BIM and related proteins. This displacement allows BIM to activate BAX/BAK, resulting in mitochondrial apoptosis. The compound shows an EC₅₀ below 5 μmol/L for apoptosis induction in MCL-1-dependent cell lines. A-1210477 displays minimal activity against other anti-apoptotic Bcl-2 family members such as Bcl-xL and Bcl-2, supporting its selectivity profile. When used in combination with navitoclax (ABT-263), a Bcl-2/Bcl-xL inhibitor, A-1210477 produces synergistic apoptosis in multiple cancer models (Fig. 3). The chemical structure is 7-(5-((4-(4-(N,N-dimethylsulfamoyl)piperazin-1-yl)phenoxy)methyl)-1,3-dimethyl-1H-pyrazol-4-yl)-1-(2-morpholinoethyl)-3-(3-(naphthalen-1-yloxy)propyl)-1H-indole-2-carboxylic acid; molecular weight 850.04.

Evidence & Benchmarks

• A-1210477 inhibits MCL-1 with Kd = 0.45 nM, demonstrating superior potency over UMI-77 (Campbell et al., 2021, DOI).
• EC₅₀ for apoptosis in MCL-1-dependent cell lines is <5 μmol/L under standard in vitro conditions (APExBIO, product page).
• MCL-1 inhibition by BH3 mimetics is fully dependent on BAX/BAK function; BAX/BAK knockout abrogates apoptosis induction (Campbell et al., 2021, DOI).
• High MCL-1 levels in breast cancer correlate with poor prognosis and stemness markers (Campbell et al., 2021, DOI).
• Combination of A-1210477 with navitoclax (ABT-263) enhances apoptosis in various cancer cell lines (Campbell et al., 2021, DOI).
• A-1210477 does not induce apoptosis in Bcl-xL- or Bcl-2-dependent cell lines, indicating high selectivity (APExBIO, product).
• Pharmacokinetic profile of A-1210477 is unfavorable for in vivo use (APExBIO, product).

This article extends the scope of "A-1210477: Selective MCL-1 Inhibitor for Cancer Research" by providing updated mechanistic details and benchmarking data relevant to clinical model systems. For more advanced workflow strategies and troubleshooting in mitochondrial apoptosis assays, see this guide. To explore how A-1210477 dissects Bcl-2 dependency beyond standard protocols, refer to the cancer cell apoptosis case study.

Applications, Limits & Misconceptions

A-1210477 is optimized for in vitro research on mitochondrial apoptosis and Bcl-2 family protein pathway dissection. It is used to validate MCL-1 dependency in cancer cell lines, screen for apoptosis sensitizers, and model drug synergy with Bcl-2/Bcl-xL inhibitors. Its specificity enables mechanistic studies of caspase signaling and mitochondrial membrane permeabilization. The compound is not suitable for in vivo efficacy studies due to poor bioavailability and rapid clearance. A-1210477 is intended for research use only; it is not for diagnostic or clinical applications.

Common Pitfalls or Misconceptions

• Not effective in Bcl-xL or Bcl-2 dependent lines: A-1210477 shows minimal activity in cell lines where survival depends on Bcl-xL or Bcl-2, not MCL-1.
• Unsuitable for in vivo use: Due to rapid metabolic clearance and poor solubility, A-1210477 is not appropriate for animal studies.
• Solubility limitations: The compound is insoluble in water and ethanol; DMSO is required, and warming/sonication may be needed for high concentrations.
• Not a diagnostic or therapeutic agent: A-1210477 is strictly for research use and not approved for clinical or diagnostic procedures.
• Non-canonical MCL-1 functions: BH3 mimetics like A-1210477 only block the canonical anti-apoptotic activity of MCL-1, not reported roles in metabolism or DNA repair.

Workflow Integration & Parameters

For apoptosis induction assays, A-1210477 should be prepared in DMSO; typical working concentrations range from 0.1 μmol/L to 10 μmol/L. Warming and sonication may be necessary to achieve full solubilization. Store the solid at -20°C and avoid prolonged storage of solutions. Mitochondrial membrane potential, caspase activation, and cytochrome c release are standard readouts. Combination studies with navitoclax (ABT-263) should use sub-lethal doses of each compound to assess synergy. For protocol optimization and troubleshooting, the workflow guide provides detailed steps and practical advice.

Conclusion & Outlook

A-1210477 (MCL-1 inhibitor, SKU B6011) from APExBIO is a validated, research-grade probe for dissecting the role of MCL-1 in cancer cell survival and apoptosis. Its selectivity and nanomolar potency make it a benchmark tool for Bcl-2 family pathway research in vitro. As MCL-1 emerges as a therapeutic target in multiple malignancies, A-1210477 facilitates preclinical studies and mechanism-of-action investigations. Continued development of MCL-1 inhibitors with improved pharmacokinetics is necessary for clinical translation. For full specifications and ordering, see the A-1210477 product page.